ARVINAS INC. - COMMON STOCK

Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs

03 Oct 2022 06:00:00 By Nasdaq GlobeNewswire

Arvinas Gives Back to Local Greater New Haven Community

30 Sep 2022 08:00:00 By Nasdaq GlobeNewswire

Arvinas to Present at Bank of America Securities Precision Oncology Conference

26 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

Arvinas to Present at Upcoming Investor Conferences

31 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

Arvinas Announces Changes to its Board of Directors

18 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

Arvinas Appoints Lisa Sinclair as Senior Vice President, Corporate Operations

15 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update

04 Aug 2022 06:00:01 By Nasdaq GlobeNewswire

Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference

02 Jun 2022 15:00:00 By Nasdaq GlobeNewswire

Arvinas Launches Global Early Career Researcher Award and Announces Call for Nominations

01 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update

05 May 2022 06:00:02 By Nasdaq GlobeNewswire

Arvinas to Present at Bank of America Securities 2022 Healthcare Conference

03 May 2022 06:00:01 By Nasdaq GlobeNewswire

Arvinas to Present at Upcoming Investor Conferences

04 Mar 2022 06:00:00 By Nasdaq GlobeNewswire

Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer

17 Feb 2022 07:00:02 By Nasdaq GlobeNewswire

Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting

14 Feb 2022 17:04:45 By Nasdaq GlobeNewswire

Arvinas to Present at Upcoming Investor Conferences

03 Feb 2022 15:30:00 By Nasdaq GlobeNewswire

Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer

10 Dec 2021 07:10:00 By Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium

19 Nov 2021 08:55:23 By Nasdaq GlobeNewswire

Arvinas to Present at Stifel 2021 Virtual Healthcare Conference

10 Nov 2021 06:00:01 By Nasdaq GlobeNewswire

Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update

03 Nov 2021 06:00:01 By Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Virtual Investor Conferences

01 Sep 2021 06:00:00 By Nasdaq GlobeNewswire